kymera patient portal

Why Kymera?

407 W. Country Club Rd. Roswell, NM 88201. 575-627-9110. Carlsbad Cancer Center and Primary Care. 101 S Canal St. Carlsbad, NM 88220. 575-234-1466. Hobbs Cancer Center and Primary Care. 3028 N Grimes St.

What is Kymera cancer&Rheumatology treatment center?

Kymera Independent Physicians is dedicated to providing accessible, innovative, superior quality health care to the residents of Roswell, Carlsbad, Hobbs and the surrounding communities of Southeastern New Mexico. Kymera accepts most private insurance, self-pay, Medicare, Medicaid, Tricare, and indigent.

What is Kymera's STAT3 target?

Jan 18, 2022 · Targeted Protein Degradation. A New Way to Treat Disease. Kymera is a clinical stage biopharmaceutical company developing novel protein degrader therapeutics to treat disease in powerful new ways, which harness the body’s natural protein degradation system to selectively degrade disease causing proteins with the goal of completely removing them from …

Targeted Protein Degradation

Kymera is a clinical stage biopharmaceutical company developing novel protein degrader therapeutics to treat disease in powerful new ways, which harness the body’s natural protein degradation system to selectively degrade disease causing proteins with the goal of completely removing them from the body.

A Powerful Drug Discovery Engine

Kymera has developed a proprietary targeted protein degradation platform called Pegasus which enables the design of highly selective small molecule protein degraders – heterobifunctional molecules with potent activity against disease-causing proteins.

Who is Kymera Medical?

Founded by Dr. Masoud Khorsand, a Roswell resident and physician as Southeastern New Mexico Internal Medicine, Kymera has grown to become an integral part of the SENM community, providing superior medical services and treatments to thousands of our neighbors each year.

Does Kymera accept Medicare?

Kymera accepts most private insurance, self-pay, Medicare, Medicaid, and Tricare. By providing outstanding cancer care in Roswell, patients from throughout Southeastern New Mexico were seeking out the services of Dr. Khorsand.

Who is Dr. Khorsand?

Starting the practice with Hematology and Oncology Dr. Khorsand has been providing cancer treatments and care for patients with blood disorders since 1998. His method is to apply time-tested approaches while continuing to stay on top of current research and treatments.

Online Physician Orders and Referrals

Accurate, Trackable Orders and Referrals: Create a complete, accurate and trackable order or referral with just a few clicks of your mouse.

Convenient, Secure Information Exchange

Secure Document Exchange: Attach H&P, care plans and other documents so providers have the information they need to provide the best care and avoid duplication.

Broader, Connected Community Healthcare

Network Building Tools: Create a solid, coordinated referral structure for your practice by connecting online with specialists and primary providers, and tracking referral patterns.

A New Wave of Transformational Therapies

Kymera is leveraging its knowledge and pre-clinical data packages to rapidly advance multiple drug candidates to the clinic – promising new therapies designed to treat serious immune inflammatory diseases and cancers with limited or no known treatment options.

IRAK4

The role of the IL-1R/TLR pathway has been demonstrated in several inflammatory and autoimmune diseases, including atopic dermatitis (AD), Hidradenitis suppurativa (HS), macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis (RA).

IRAKIMiD

Kymera is developing novel heterobifunctional degraders that target degradation of both IRAK4 and IMiD substrates Ikaros and Aiolos with a single small molecule, addressing both the IL-1R/TLR and the Type 1 IFN pathways synergistically to broaden activity against MYD88-mutant DLBCL.

STAT3

A target long considered “undruggable,” STAT3 is a transcriptional regulator that has been linked to numerous cancers and other inflammatory and autoimmune diseases. Kymera is developing selective STAT3 degraders for the treatment of hematological malignancies and solid tumors, as well as autoimmune diseases and fibrosis.

Discovery Programs

We are taking advantage of our proprietary E3 Ligase Whole-Body Atlas on the differential expression profile of E3 ligases to pursue targets that can benefit from potentially tissue-restricted degradation. Our early pipeline includes programs in genetically defined oncology and immunology indications.

Powered for Partnership

We believe in exploring potential synergies with the biopharmaceutical industry to accelerate the path forward to becoming a fully integrated biotechnology company and delivering transformative therapies to the broadest possible patient populations.